Welcome to our dedicated page for Lexaria Bioscience Warrant news (Ticker: LEXXW), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscience Warrant stock.
Lexaria Bioscience Corp. (NASDAQ:LEXXW) is a global innovator in drug delivery platforms known for its patented drug delivery technology, DehydraTECH. DehydraTECH enhances the absorption of active pharmaceutical ingredients, such as cannabinoids and nicotine, by promoting more effective oral delivery. The technology has shown to significantly increase bio-absorption, reduce onset times, and mask unwanted tastes. Lexaria operates in four main segments: Intellectual Property Licensing, B2B Production, Research and Development, and Corporate. With a robust intellectual property portfolio and ongoing research, Lexaria aims to revolutionize drug delivery methods and improve outcomes.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced that its DehydraTECH technology effectively inhibited the COVID-19 SARS-CoV-2 virus in an in vitro study using remdesivir and ebastine. The study's preliminary results confirmed the antiviral efficacy of these compounds, paving the way for future in vivo testing. The global antiviral market is projected to exceed USD $44 billion by 2026. Lexaria aims to enhance the oral delivery of these drugs, addressing key challenges in their bioavailability.
Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW) announced remarkable results from its latest DehydraTECH 2.0 cannabidiol (CBD) formulation, achieving a 2,708% improvement in CBD absorption compared to the standard MCT control. This formulation outperformed previous versions, increasing efficacy by 174% over the original DehydraTECH 2.0. The ongoing HYPER-H21-1 human clinical hypertension study is expected to further validate these advancements. Lexaria's research, focused on enhancing drug delivery, positions it favorably in the burgeoning CBD market.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) has announced its first patent grant in India, expanding its intellectual property portfolio to a total of 19 patents worldwide. This new patent, titled Stable ready-to-drink beverage compositions comprising lipophilic active agents, is valid for 20 years from December 1, 2016. The patent enhances Lexaria's existing protections in the EU, U.S., and Australia, allowing innovation in ready-to-drink beverages that include various active ingredients like NSAIDs and cannabinoids. Lexaria's patented technology, DehydraTECH™, improves the bio-absorption of these compounds.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced favorable results from its first animal study and the initiation of its first human clinical study as part of its 2021 Hypertension R&D program. CEO Chris Bunka will present at the Benzinga Global Small Cap Conference on May 13, 2021, at 3:50 p.m. ET. The presentation will cover Lexaria's DehydraTECH™ drug delivery technology and its effectiveness in enhancing the delivery of cannabidiol (CBD) for hypertension and other applications. The event aims to connect small-cap companies with investors.
Lexaria Bioscience Corp. (NASDAQ:LEXX, NASDAQ:LEXXW) announced successful results from its 2021 study HYPER-A21-1, showcasing its DehydraTECH 2.0 formulations. These new formulations delivered up to 2,178% more CBD into the bloodstream and 1,737% more into brain tissue compared to a standard MCT oil control. The study involved ten rats receiving a 25 mg/Kg dose of CBD over 120 minutes. CEO Chris Bunka emphasized the substantial absorption efficiency of these formulations, which are anticipated to have applications in both pharmaceutical and consumer product markets.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) has launched its human clinical hypertension study HYPER-H21-1, examining the effectiveness of its patented DehydraTECH CBD formulation in controlling blood pressure. The study involves 24 volunteers and aims to complete dosing within weeks, with preliminary results expected by July. Secondary objectives include assessing the absorption rate of CBD and related metabolites. Lexaria has 18 granted patents and anticipates further studies to support DehydraTECH's validity as a hypertension treatment. Final results are scheduled for early September 2021.
Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) announces the appointment of Gregory Downey as the new Chief Financial Officer effective April 15, 2021. Downey, previously the Company's Controller, brings over ten years of CFO experience and will be compensated with a CDN$144,000 annual salary, a 10% increase, and stock options. The Company also plans to issue 300,000 share purchase warrants to third-party consultants, exercisable until April 16, 2024, at US$9.00 per share. Lexaria continues to advance its DehydraTECH technology for improved drug delivery.
Lexaria Bioscience Corp. (NASDAQ:LEXX) announced that its client Amari Corp.'s "Everyday Calm" CBD product was recognized as a Top CBD Product Pick by New Hope Network during the Natural Products Expo 2020. This accolade underscores the effectiveness of Lexaria's DehydraTECH technology, which enhances CBD delivery for improved consumer satisfaction. The DehydraTECH platform demonstrates a potential increase in bio-absorption by up to 10x, essential for the growth of CBD products in retail. Lexaria aims to expand the reach of its technology across multiple product formats.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) announced its largest-ever R&D initiative for 2021, targeting four drug markets with a potential value of $87 billion. The studies will focus on enhancing delivery systems for NSAIDs, THC, nicotine, and sildenafil using the DehydraTECH technology. Key market insights include the NSAID market expected to grow to $24.4 billion by 2027 and the cannabis market projected at $40.6 billion by 2024. These initiatives aim to improve drug absorption and speed, with test articles scheduled for manufacturing and dosing in the coming months.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced successful stability testing for its DehydraTECHTM CBD-infused beverages, revealing a remarkable 93.4% potency retention one year post-production. This ensures excellent microbial purity and consistent CBD distribution without physical mixing, addressing common beverage degradation challenges. The technology, which significantly enhances cannabinoid absorption, is poised for broader applications, and Lexaria continues its industry leadership in innovative drug delivery systems.
FAQ
What is the current stock price of Lexaria Bioscience Warrant (LEXXW)?
What is Lexaria Bioscience Corp. known for?
In which segments does Lexaria operate?
What are the key benefits of DehydraTECH?
What is the main goal of Lexaria Bioscience Corp.?
How does DehydraTECH impact drug delivery across the blood-brain barrier?
What is the significance of Lexaria's intellectual property portfolio?
Who owns and manufactures GLP-1 drugs like Rybelsus and Ozempic?
What is the focus of Lexaria's ongoing research?
How does Lexaria plan to enhance the delivery of tirzepatide in its latest Study?
What sets Lexaria Bioscience Corp. apart from other innovators in drug delivery platforms?
